Targovax announces opening of Oslo University Hospital as site for ONCOS-102 trial in melanoma
Oslo, Norway, 24 September 2019 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that Oslo University Hospital, has been included as a site in the ongoing ONCOS-102 trial in anti-PD1 refractory, advanced melanoma. Recently, Targovax reported encouraging results from Part 1 of the phase I trial in anti-PD1 refractory melanoma combining ONCOS-102 with the checkpoint inhibitor Keytruda, showing 33% ORR and robust immune activation (see press release here